The hospital operator released preliminary financial results and guidance for 2020.
These oil companies could reap the benefits if crude prices jump this year.
The company is offering to buy back shares from investors at a big premium.
The clinical-stage company has inked a new deal with a big biopharma.
The company announced a string of deals over the weekend that failed to spark investors' optimism.
Fast-approaching catalysts could make these biotech stocks top performers this year.
In a bid to increase legal marijuana sales, Governor Newsom is proposing to overhaul the current regulatory system.
A promising clinical trial update has investors increasingly optimistic about the company's pipeline.
A new deal accelerates the company's shift to a commercial-stage biotech.
The company's restructuring strategy appears to be paying off for investors.
A sneak peek at its fourth-quarter financial performance is fueling investors' optimism.
A strong economy fueled double-digit growth at this human resources software company.
Demand for the company's minimally invasive surgical approach continues to outpace the broader spine surgery market.
Rapid sales growth for its tardive dyskinesia drug fueled investor optimism.
The company's 3D sensing technology is increasingly being incorporated into next-generation consumer electronic devices.
Investors are locking in gains in this fast-growing drugmaker.
These strategies can help you collect more money from Social Security in retirement.
The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.
The company's clinical trial is taking an important step forward.
Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.